Lyell Immunopharma (NASDAQ: LYEL) has recently received a number of price target changes and ratings updates:
- 6/15/2026 – Lyell Immunopharma had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $34.00 price target on the stock.
- 6/15/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.
- 6/9/2026 – Lyell Immunopharma had its “market outperform” rating reaffirmed by Citigroup Inc..
- 6/9/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
- 6/8/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.
- 6/3/2026 – Lyell Immunopharma was given a new $45.00 price target by Needham & Company LLC.
- 6/3/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
- 5/18/2026 – Lyell Immunopharma was upgraded by Zacks Research from “strong sell” to “hold”.
- 5/10/2026 – Lyell Immunopharma was upgraded by Wall Street Zen from “sell” to “hold”.
- 5/7/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.
- 5/2/2026 – Lyell Immunopharma was downgraded by Wall Street Zen from “hold” to “sell”.
- 4/30/2026 – Lyell Immunopharma was given a new $49.00 price target by Robert W. Baird. They now have an “outperform” rating on the stock.
- 4/30/2026 – Lyell Immunopharma was upgraded by Robert W. Baird to “strong-buy”.
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
See Also
- Five stocks we like better than Lyell Immunopharma
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
- onsemi: What the Market Gets Wrong, You Can Get Right
- Is McCormick a Steal Ahead of Game-Changing Unilever Deal?
Receive News & Ratings for Lyell Immunopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.
